ETFs
A
ATR
Aptargroup
124.73
+0.65+0.52%Pre Market: 123.92 -0.81 -0.65%04:24 04/28 EDT
OPEN/PREV CLOSE126.12/124.73
TODAY RANGE123.72-126.65
VOL1
MARKET CAP8.02B
52 WEEK RANGE102.83-163.04
AVG VOL (3M)529.15K
% TURNOVER0.56%
TURNOVER0
P/E (TTM)21.37
% RANGE2.03%
EPS(TTM)5.89
P/E(FORWARD)23.29
P/B3.026
BVPS41.56
DIVIDEND1.920
P/S2.138
BETA--
DIV YIELD1.53%
FREE FLOAT MKT CAP7.95B
SHARES OUTSTANDING63.77M
NEXT EARNINGS02/04-02/09
FREE FLOAT63.22M
LOT SIZE1
EX-DATE05/06/2026
News
Press Releases
Financial Reports
Profile
Simply Wall St·11h ago
How AptarGroup’s Lidless SimpliSqueeze Push Into New Categories And Dividend Move At AptarGroup (ATR) Has Changed Its Investment Story
Simply Wall St·4d ago
AptarGroup Climate Leader Status Meets Undervalued Stock And ESG Appeal
Seeking Alpha·5d ago
AptarGroup declares $0.48 dividend
Simply Wall St·5d ago
Is There Now An Opportunity In AptarGroup (ATR) After Recent Share Price Weakness
TipRanks·04/21 09:16
AptarGroup (ATR) Gets a Buy from Raymond James
Simply Wall St·04/11 00:33
Is Aptar’s Enable Injections Digital Partnership Reframing the Drug Delivery Narrative for AptarGroup (ATR)?
TipRanks·04/06 13:53
AptarGroup price target lowered to $145 from $147 at BofA
TipRanks·04/06 11:15
AptarGroup (ATR) Gets a Hold from Bank of America Securities
Simply Wall St·04/01 12:34
How Investors May Respond To AptarGroup (ATR) Powering ENA’s Phase II Intranasal Antiviral Study
Simply Wall St·03/27 18:10
Assessing AptarGroup (ATR) Valuation After Recent Share Price Weakness
NASDAQ·03/26 09:43
New Strong Sell Stocks for March 26th
Simply Wall St·03/25 03:17
Did CEO Succession and Nasal Drug Collaborations Just Shift AptarGroup's (ATR) Investment Narrative?
Simply Wall St·03/22 06:04
AptarGroup’s Nasal Devices Gain Ground In Respiratory Trials And Leadership Shift
Benzinga·03/20 14:06
Wells Fargo Upgrades AptarGroup to Overweight, Raises Price Target to $144
Same Industry
Name/Symbol
Change%
Price